Singapore is managing a new COVID-19 wave that pushed weekly infections to 12,700 in the week of May 10 to 16, 2026 — a jump of nearly 60% from 8,000 cases the week prior, according to Singapore's Communicable Diseases Agency (CDA).
The surge is being driven by NB.1.8.1, a descendant of the JN.1 Omicron lineage now accounting for more than half of all locally sequenced COVID-19 cases in the city-state. Simultaneously, data from the World Health Organization's Western Pacific Regional Office shows Singapore posted the region's highest combined influenza and SARS-CoV-2 positivity rate at 17% during epidemiological week 21 — making it both a COVID and flu concern heading into June.
NB.1.8.1: What Is the "Nimbus" Variant?
NB.1.8.1, informally called "Nimbus," has been classified by the World Health Organization as a Variant Under Monitoring (VUM) due to its demonstrated growth advantage over previously circulating strains and its rapid spread across multiple Asian countries, including Singapore, Hong Kong, and India.
The CDA has been explicit that there is currently no evidence NB.1.8.1 is more transmissible or causes more severe illness than earlier variants. However, subtle mutations in its spike protein appear sufficient to partially evade immune memory built up from prior infections or vaccinations — which, combined with waning population immunity over time, is contributing to the current wave.
Globally, much of Europe and North America are tracking a different lineage — the RV.1 variant and its relatives. Singapore's NB.1.8.1-led surge reflects regional travel patterns and local viral ecosystems in Southeast Asia, where the strain has taken root and spread rapidly.
| Data Point | Detail |
| Weekly cases (May 10–16, 2026) | 12,700 |
| Prior week cases (May 3–9, 2026) | 8,000 |
| Week-over-week increase | ~59% |
| Average daily hospitalizations | Rose from 56 to 73 |
| Average daily ICU cases | ~1 |
| Dominant variant | NB.1.8.1 (>50% of sequenced cases) |
| WHO classification of NB.1.8.1 | Variant Under Monitoring (VUM) |
| Singapore SARS-CoV-2 + influenza positivity (Week 21) | 17% (highest in Western Pacific region) |
| Hospital capacity status | Adequate — hospitals managing without strain |
A Dual Respiratory Threat: COVID-19 and Influenza Co-Circulating
One aspect of the current situation that deserves attention is the simultaneous elevation of both COVID-19 and influenza transmission in Singapore. The WHO Western Pacific bulletin from June 4, 2026 noted that Singapore's influenza positivity rate — like its SARS-CoV-2 rate — had trended upward through late May, with both reaching 17% in week 21 of 2026.
That co-circulation creates diagnostic and clinical complexity. Both diseases present with fever, body aches, and respiratory symptoms. Without testing, patients and even clinicians may struggle to distinguish them. It also increases the likelihood of co-infection, which can worsen outcomes in vulnerable individuals.
The CDA noted the increase in cases could be linked to several factors, with waning population immunity identified as the primary driver. As time elapses since the last vaccination or COVID-19 infection, community-level protection diminishes — a pattern seen globally as COVID-19 settles into an endemic respiratory disease cycle.
Who Is Most at Risk?
While most healthy adults with current or recent immunity are expected to experience mild to moderate illness from NB.1.8.1, the CDA has specifically called on the following groups to ensure their vaccinations are up to date:
- Adults aged 60 years and above, including those in aged-care facilities
- Individuals with chronic illnesses such as diabetes, heart disease, or chronic lung conditions
- Immunocompromised individuals
- Healthcare workers
Average daily hospitalizations rose from 56 to 73 during the week of May 10–16. ICU admissions have remained low at approximately one case per day, and Singapore's public hospitals have confirmed they are managing the increase without capacity concerns.
Vaccination: Is Singapore's Current Shot Effective Against NB.1.8.1?
The CDA has confirmed that Singapore's current COVID-19 vaccines — including the JN.1-updated formulations from Pfizer-BioNTech/Comirnaty, Moderna/Spikevax, and Novavax/Nuvaxovid — retain effectiveness against NB.1.8.1. Vaccination is free under Singapore's National Vaccination Programme (NVP) for citizens, permanent residents, long-term pass holders, and certain short-term pass holders.
Singapore's health authorities have urged higher-risk residents who have not been vaccinated in the past year to come forward. Those who received the JN.1 vaccine in 2024/2025 and wish to receive the JN.1 Novavax/Nuvaxovid formulation are also eligible.
Is Singapore's COVID Surveillance Keeping Pace?
Unlike the height of the pandemic, COVID-19 is no longer a legally notifiable disease in Singapore. Individual case counts are no longer publicly reported in real time — the CDA issues estimated case counts based on sampling and sentinel surveillance. While this approach is consistent with endemic disease management globally, it means the public is working with modeled estimates rather than confirmed totals.
The CDA's transparency in issuing timely public statements and its regular Weekly Infectious Diseases Bulletin are noteworthy positives. Still, the lack of granular location-specific data — such as which neighborhoods or building types are seeing the highest case clusters — limits residents' ability to make fully informed decisions about masking and crowded-space avoidance.
What to Know About COVID-19 Symptoms and When to Seek Care
Common symptoms of COVID-19 — including NB.1.8.1 — include fever, cough, sore throat, runny nose, body aches, and fatigue. Some patients report loss of taste or smell, though this symptom has become less common with Omicron-lineage variants.
Residents should seek immediate medical care if they develop difficulty breathing, persistent chest pain or pressure, confusion, or an inability to stay awake — these are signs of severe disease requiring emergency attention. High-risk individuals who test positive are encouraged to contact their GP or polyclinic promptly about antiviral treatment options such as Paxlovid, which is most effective when started within five days of symptom onset.
Frequently Asked Questions
How serious is Singapore's current COVID-19 wave?
Weekly cases jumped to 12,700 in mid-May 2026 — a nearly 60% surge in one week. Hospitalizations rose, but hospitals remain at manageable capacity. ICU admissions are low at about one per day. The CDA says there is no evidence that the circulating variant causes more severe illness than previous strains.
What is the NB.1.8.1 "Nimbus" variant?
NB.1.8.1 is a descendant of the Omicron JN.1 lineage. It has been classified as a Variant Under Monitoring by the WHO due to its growth advantage over earlier strains. It is currently the dominant COVID variant in Singapore, accounting for more than half of sequenced cases.
Are current COVID vaccines effective against NB.1.8.1?
Yes. Singapore's CDA has confirmed that existing JN.1-updated vaccines from Pfizer-BioNTech, Moderna, and Novavax remain effective against NB.1.8.1. Vaccination is free under Singapore's National Vaccination Programme.
Should travelers to Singapore be concerned about COVID?
Travelers should be aware of the active wave and ensure they are up to date on COVID-19 vaccinations before traveling. Singapore's hospitals are managing the situation, and there are no travel restrictions. High-risk travelers — seniors and those with chronic illness — should take extra precautions.
Why are COVID cases rising again in Singapore?
The CDA attributes the surge primarily to waning population immunity over time, combined with the partial immune evasion properties of the NB.1.8.1 variant. These periodic waves are expected as COVID-19 circulates as an endemic disease.
